The US Food and Drug Administration has approved a new indication for the use of Japanese drug major Astellas Pharma (TYO: 4503) and Medivation’s (Nasdaq: MDVN) Xtandi (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC).
This new approved use follows a priority review of the supplemental New Drug Application (sNDA) that was based on results of the Phase III PREVAIL trial. The news pushed Medivation’s shares 2.7% higher to $96.89 in after-hours US trading yesterday, while Astellas gained 2.25% to 1,544.5 yen in Japanese afternoon trading today.
The approval of this new indication for Xtandi triggers $90 million in milestone payments to Medivation under its collaboration agreement with Astellas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze